{"attachment":[{"description":"","display":"1","file":{"id":"1459936","resource":"file","uuid":"bd47f7e4-3549-414a-b6a9-6a6917732c49"}}],"body":"<p>WILMINGTON, Del. – Novum Pharmaceutical Research Services of Delaware, Inc. (“Novum”), a Delaware corporation with its principal place of business in Pittsburgh, Pennsylvania, has agreed to pay $3,345,000 to resolve allegations that it improperly obtained a Paycheck Protection Program (“PPP”) loan from the U.S. Small Business Administration (“SBA”) for which it was not eligible.</p><p>PPP was an emergency loan program established by Congress in March 2020 under the Coronavirus Aid, Relief, and Economic Security Act and administered by the SBA.&nbsp; The program was created to support small businesses and to help them continue to pay employees and meet other business expenses during the COVID-19 pandemic.&nbsp; A second round of loans was authorized in early 2021.&nbsp; To be eligible for these Second Draw PPP loans, a business was required to certify that it had no more than 300 employees, including employees of all domestic and foreign affiliates.&nbsp;</p><p>Novum applied for and received a $2,000,000 Second Draw PPP loan.&nbsp; In its loan application, Novum certified that, together with its affiliates, it had fewer than 300 employees, as required for eligibility.&nbsp; Novum later applied for—and ultimately received—full forgiveness of the Second Draw loan.&nbsp; However, at the time of its application, Novum and its domestic and foreign affiliates, including its ultimate parent, India-based Lambda Therapeutic Research, Ltd., collectively employed more than 300 individuals.&nbsp; As a result, Novum was not eligible for a Second Draw PPP loan under the SBA’s employee‑based size standard.</p><p>U.S. Attorney Benjamin L. Wallace announced the settlement.&nbsp; Assistant U.S. Attorney Jacob Laksin handled the case.&nbsp;</p><p>The civil settlement includes the resolution of claims brought under the <em>qui tam&nbsp;</em>or whistleblower provisions of the False Claims Act.&nbsp; Under those provisions, a private party—known as a relator—can file an action on behalf of the United States and receive a portion of any recovery.&nbsp; In this case, the relator will receive a share of the settlement.</p><p>Individuals with information about allegations of fraud involving COVID-19 are encouraged to report it by calling the Department of Justice’s National Center for Disaster Fraud (NCDF) Hotline at 866-720-5721 or via the NCDF Web Complaint Form at: <a href=\"https://www.justice.gov/disaster-fraud/ncdf-disaster-complaint-form\">https://www.justice.gov/disaster-fraud/ncdf-disaster-complaint-form</a>.</p><p>On April 7, the Department of Justice announced the creation of the National Fraud Enforcement Division (“Fraud Division”).&nbsp; The Fraud Division is investigating and prosecuting those who commit fraud against the American people.&nbsp; The Department’s work to combat fraud supports President Trump’s Task Force to Eliminate Fraud, a whole-of-government effort chaired by Vice President J.D. Vance to eliminate fraud, waste, and abuse within federal benefit programs.&nbsp;</p><p>A copy of this press release is located on the website of the&nbsp;<a href=\"https://www.justice.gov/usao-de\">U.S. Attorney’s Office</a> for the District of Delaware.&nbsp; A copy of the settlement agreement and agreed-upon statement of facts are attached to this press release.<em>&nbsp;</em>Related court documents and information are&nbsp;located on the website of the&nbsp;<a href=\"https://www.ded.uscourts.gov/\">District Court</a> for the District of Delaware or on <a href=\"https://pcl.uscourts.gov\">PACER</a> by searching for Case No. 24-cv-1381-GBW.</p><p><em>The claims resolved by the settlement are allegations only; there has been no determination of liability.</em></p><p class=\"text-align-center\">&nbsp;</p><p class=\"text-align-center\">&nbsp;</p><p><a href=\"https://www.justice.gov/usao-de/media/1459936/dl?inline\">Novum Settlement Agreement</a></p>","changed":"<time datetime=\"2026-09-02T12:46:49-04:00\">1788367609</time>\n","component":[{"name":"USAO - Delaware","uuid":"c0b87f89-7a91-4fde-8d5a-549b5458a6f7"}],"created":"<time datetime=\"2026-09-01T16:27:33-04:00\">1788294453</time>\n","date":"1788264000","image":"","number":"","teaser":"<p>Novum Pharmaceutical Research Services of Delaware, Inc. (“Novum”), a Delaware corporation with its principal place of business in Pittsburgh, Pennsylvania, has agreed to pay $3,345,000 to resolve allegations that it improperly obtained a Paycheck Protection Program (“PPP”) loan from the U.S. Small Business Administration (“SBA”) for which it was not eligible.</p>","title":"Delaware Company to Pay More Than $3.34 Million to Resolve False Claims Act Allegations Related to Paycheck Protection Program Loan","topic":[{"name":"False Claims Act","uuid":"87816596-1bad-44b8-b138-df98755a6895"},{"name":"COVID-Related Fraud","uuid":"6827a162-b783-4ffa-a6c2-596fc9f07e39"}],"url":"https://www.justice.gov/usao-de/pr/delaware-company-pay-more-334-million-resolve-false-claims-act-allegations-related","uuid":"e55af55a-9723-403b-94e5-667937646e1b"}